Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
AZD8965 low dose · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Placebo for AZD8965 | PLACEBO_COMPARATOR | Placebo for AZD8965 |
| AZD8965 low dose | EXPERIMENTAL | AZD8965 low dose |
| AZD8965 medium dose | EXPERIMENTAL | AZD8965 medium dose |
| AZD8965 high dose | EXPERIMENTAL | AZD8965 high dose |
| Name | Type | Description |
|---|---|---|
| Placebo for AZD8965 | OTHER | Placebo for AZD8965 |
| AZD8965 low dose | DRUG | AZD8965 low dose |
| AZD8965 medium dose | DRUG | AZD8965 medium dose |
| AZD8965 high dose | DRUG | AZD8965 high dose |
Inclusion Criteria: 1. Age ≥ 40 years 2. IPF diagnosis 3. Participants with IPF receiving locally approved antifibrotic therapies at a stable dose, or participants with IPF not receiving local standard of care 4. FVC ≥ 45% predicted of normal 5. DLCO corrected for hemoglobin ≥ 25% predicted of norm...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Bristol-Myers Squibb Company | BMY | 2 | PHASE3 | BMS-986278 |
| United Therapeutics Corporation | UTHR | 2 | PHASE3 | Treprostinil |
| AbbVie, Inc. | ABBV | 2 | PHASE2 | ABBV-142 |
| PureTech Health PLC Sponsored ADR | PRTC | 2 | PHASE3 | Deupirfenidone, Pirfenidone |
| Syndax Pharmaceuticals Inc | SNDX | 1 | PHASE2 | Axatilimab |
| Contineum Therapeutics, Inc. Class A | CTNM | 1 | PHASE2 | PIPE-791 Dose A, PIPE-791 Dose B |
| Rein Therapeutics, Inc | RNTX | 1 | PHASE2 | LTI-03 |
| Sunshine Biopharma Incorporated | SBFM | 2 | PHASE3 | HEC585, Pirfenidone |
| Cumberland Pharmaceuticals Inc. | CPIX | 1 | PHASE2 | Ifetroban |
| Avalyn Pharma Inc | AVLN | 3 | PHASE2 | AP01 |
AZD8965 is an investigational small molecule being developed for idiopathic pulmonary fibrosis (IPF) and is also studied in healthy participants. It is currently in Phase 1 clinical development, with a Phase 2b trial recruiting participants with IPF.
AZD8965 is being developed by AstraZeneca PLC, a biopharmaceutical company listed on the stock exchange under the ticker AZN.
AZD8965 is in Phase 1 clinical development. A Phase 1 study in healthy participants has been completed, and a Phase 2b trial in participants with idiopathic pulmonary fibrosis is currently recruiting.
AZD8965 has one completed Phase 1 trial (NCT06502379) in healthy participants, including Japanese and Chinese participants, and one recruiting Phase 2b trial (NCT07652658) in participants with IPF.
Yes, AZD8965 is also known as AZD8965 low dose. Both names refer to the same investigational drug being developed by AstraZeneca.
AZD8965 is not FDA approved. It is an investigational drug currently in clinical development, with a completed Phase 1 study and an ongoing Phase 2b trial in idiopathic pulmonary fibrosis.